BioCryst Pharmaceuticals, Inc. (BCRX)

In the past six months, BioCryst's stock was positively influenced by strong financial results, including a significant beat on Q4 2025 earnings and substantial year-over-year revenue growth. The FDA approved an oral pellet formulation of ORLADEYO for pediatric patients aged 2 to less than 12 years, expanding its market. BioCryst completed the acquisition of Astria Therapeutics for approximately $700 million, introducing uncertainty but also adding pipeline assets. The stock experienced surges driven by speculation of a potential acquisition, and insider selling activity was noted.

Demand seasonality for BioCryst Pharmaceuticals' products is not explicitly detailed; however, ORLADEYO's demand is unlikely to be subject to significant seasonal fluctuations, while RAPIVAB could potentially experience some seasonality aligned with influenza seasons. The company's focus on rare diseases generally suggests a more consistent demand profile.

BioCryst Pharmaceuticals, Inc. specializes in developing oral drugs for rare and serious diseases, with major marketed products including ORLADEYO for hereditary angioedema and RAPIVAB for influenza. The company's pipeline includes BCX10013, navenibart, STAR-0310, BCX17725, Avoralstat and Galidesivir.

BioCryst Pharmaceuticals is headquartered in Durham, North Carolina, with a Discovery Center in Birmingham, Alabama, and other regional offices globally. ORLADEYO is approved in the United States and in more than 45 other countries worldwide, while RAPIVAB has received approval in the U.S., Japan, Korea, and China.

BioCryst's brand reputation has been influenced by strong financial performance, with ORLADEYO sales reaching $601.8 million in 2025 and the company achieving its first full year of profitability. The FDA approval of ORLADEYO for pediatric use also contributed positively. However, the acquisition of Astria Therapeutics introduced some investor caution, and Evercore ISI downgraded BioCryst Pharmaceuticals due to increasing competition in the HAE treatment landscape. Takeover speculation also created volatility.

BioCryst Pharmaceuticals, Inc. has significant institutional ownership, with approximately 83.18% to 85.88% of its stock held by institutional investors. Insiders hold about 1.55% to 5.10% of the stock, while retail investors account for approximately 1.60% to 37.99%. Baker Bros Advisors LP is noted as the largest individual shareholder.